CCR News and Events
Potent new LDHI inhibitor disrupts tumor growth in mice
Researchers have identified a potent LDH inhibitor, which can disrupt the energy production of tumors in mice. After exposure to the LDH inhibitor, the cancers cells began to rely on a different form of energy production, which could also be disrupted by using a second drug. Combining the two drugs had a potent anti-cancer effect. Read more...
Clinical trial investigates IV administration of vaccine for advanced solid tumors
Jan 14, 2020
Marijo Bilusic, M.D., Ph.D., of the Genitourinary Malignancies Branch, is leading a clinical trial to test whether giving the MVA-BN-brachyury vaccine intravenously is safe for humans and has no intolerable side effects. The goal of the study is to see whether intravenous MVA-BN-brachyury vaccine can shrink tumors and slow or prevent the spread of cancer to other parts of the body. Read more...
FDA grants orphan drug designation to zotiraciclib for the treatment of glioma
Jan 9, 2020
The U.S. Food and Drug Administration granted orphan drug status in December to zotiraciclib for use in patients with glioma, a cancer of the brain that begins in glial cells (cells that surround and support nerve cells). This designation is based on results from an ongoing NCI-sponsored phase 1 trial led by the CCR Neuro-Oncology Branch at the NIH Clinical Center. Read more...
Protein affecting cell division hints at a way to overcome drug resistance
Jan 9, 2020
Researchers have uncovered the way in which a protein, called CLR4, helps complete the cell division process. The mechanism could potentially be harnessed to overcome resistance of cancer cells to chemotherapy drugs such as paclitaxel. Read more...
Jay Berzofsky and Hoyoung Maeng discuss new vaccine to help men with prostate cancer
Jan 7, 2020
Jay Berzofsky, M.D., Ph.D., Chief of the Vaccine Branch, and Hoyoung Maeng, M.D., Assistant Research Physician in the Vaccine Branch, recently discussed their ongoing work to design and develop vaccines and immunotherapy for cancer prevention and treatment with Cancer Therapy Advisor. They share how they are testing a vaccine that may one day delay the need to use androgen deprivation therapy (ADT) in prostate cancer patients. Read more...
Former Pediatric Oncology Branch patient donates toys to NIH Pediatric Clinic
Jan 6, 2020
In December, former patient Julie Jones donated over 1,000 toys to the Pediatric Clinic at the NIH Clinical Center. Jones is a former patient in the Pediatric Oncology Branch who was treated more than 20 years ago for alveolar rhabdomyosarcoma. She says, “I remember what it was like. What these children are going through at such a young age really breaks your heart. I’ve often said there’s nothing greater than seeing the smile on the face of a sick child.” Read more...
Binding preferences of Ras and Raf yield clues for developing targeted cancer therapies
Dec 19, 2019
Using living cells, researchers in CCR have found that a set of enzymatic proteins, known as Raf kinases, have differing affinities in how they bind to a class of cancer-related proteins, known as the Ras GTPases. This could offer new strategies for developing more effective targeted therapies. Read more...
Histone deacetylase inhibitors block cancer-driving gene networks by obstructing DNA folding
Dec 19, 2019
Studies of the pediatric cancer rhabdomyosarcoma have revealed an unexpected way to intervene in cell-identity-determining networks that are abused by many aggressive cancers. Read more...
Differences between anti-viral and anti-tumor T-cell responses could impact immunotherapy
Dec 19, 2019
A finding published in Cell Reports holds promise for resolving some of the conundrums surrounding CD4+ T cells and their potential in fighting cancer. The work found that CD4+ T-cell responses to tumor antigens are quite different from those to infections, highlighting a need to re-think how to harness the power of CD4+ T cells. Read more...
New findings hint at therapies for African Americans with lung cancer
Dec 16, 2019
A study published in Nature Communications reveals that two genes tend to be mutated at higher rates in cancerous lung tissue samples taken from African Americans, hinting that these patients may benefit more from certain therapies targeting those genes. Read more...
Christopher Buck recently featured in Nature Index article
Dec 12, 2019
Christopher Buck, Ph.D., Senior Investigator in the Laboratory of Cellular Oncology, was recently featured in a Nature Index article where he discussed US-China scientific relations and how collaboration between the two remains strong. Read more...